We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3) (CAMP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000575
Recruitment Status : Completed
First Posted : October 28, 1999
Results First Posted : April 3, 2014
Last Update Posted : April 3, 2014
National Heart, Lung, and Blood Institute (NHLBI)
CAMP Steering Committee
Information provided by (Responsible Party):
James Tonascia, Johns Hopkins Bloomberg School of Public Health

Brief Summary:
The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.

Condition or disease Intervention/treatment Phase
Asthma Lung Diseases Drug: Placebo Drug: Nedocromil Drug: Budesonide Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1041 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Childhood Asthma Management Program
Study Start Date : September 1991
Actual Primary Completion Date : October 1999
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Active Comparator: 1 Budesonide
Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn
Drug: Budesonide
Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
Other Name: Pulmicort

Active Comparator: 2 Nedocromil
Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn
Drug: Nedocromil
Four 2 mg puffs bid + two 90 Og puffs albuterol prn
Other Name: Tilade

Placebo Comparator: 3 Placebo
Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.
Drug: Placebo
Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.

Primary Outcome Measures :
  1. Pulmonary Function as Measured by Normalized FEV1 Over a 4-6 Year Period [ Time Frame: At the end of treatment, 4-6 years from baseline assessment ]
    Change in FEV1 % of predicted, post-bronchodilator use, from baseline to the end of treatment (4-6 years after randomization). Percent predicted determined from three separate published sets of reference equations for white, black, and Hispanic children - see NEJM 343: 1054-1062, 2000 for more details and references.

Secondary Outcome Measures :
  1. Bronchial Responsiveness to Serial Methacholine Concentrations Inhaled Into the Lungs [ Time Frame: 4-6 years from baseline ]
    Bronchial responsiveness to serial concentrations of inhaled methacholine solution (mg/ml) as measured by serial ratios of follow-up to baseline FEV1 (forced volume of air expired from the lungs in one second). A dose-response curve is calculated from the serial ratios in relation to the serial concentrations to determine PC20, the concentration associated with a 20% drop from baseline in FEV1; this PC20 is the outcome measure with units mg/ml of methacholine.

  2. Change From Baseline in the Rate of Asthma Free Days [ Time Frame: 4-6 years from baseline ]
    Change from baseline proportion of days without asthma symptoms or other asthma related events to proportion of days during the 4-6 years of follow-up. Asthma free days were determined from daily asthma diaries kept from baseline to the end of treatment, 4-6 years later.

  3. Need for Urgent Care for Asthma [ Time Frame: 4-6 years from baseline ]
    Counts during the period of treatment (4-6 years) of visits to emergency rooms or equivalent urgent care settings for asthma treatment.

  4. Mortality [ Time Frame: 4-6 years from baseline ]
    Counts of deaths from asthma.

  5. Change in Height From Baseline to End of Treatment, 4-6 Years Later [ Time Frame: 4-6 years from baseline ]
    Change in standing height from baseline to end of treatment. Standing height is measured three times without shoes using a calibrated Harpenden stadiometer; the average of the three repeated heights to the nearest 0.1 cm is the height measure at either baseline or end of treatment.

  6. Standardized Depression Scale -- Children's Depression Inventory [ Time Frame: 4-6 years from baseline ]
    Change in total score on the Children's Depression Inventory from baseline to the end of treatment, 4-6 years later. The total score ranges from 0-54 with higher scores indicating greater levels of depression.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Age 5 to 12 years at time of screening
  • Chronic asthma as evidenced by one or more of the following historical findings for at least 6 months during the past year:
  • Asthma symptoms at least 2 times per week
  • 2 or more usages per week of an inhaled bronchodilator
  • Daily asthma medication
  • Current asthma symptoms either by diary symptom code of 1 or greater or am or pm PEFR less than 80% of personal best post-bronchodilator value by diary, on 8 or more days during the prn screening period
  • Methacholine sensitivity: estimated PC20 FEV1 less than or equal to 12.5 mg/ml
  • Consent of guardian and assent of child
  • Ability to comply with trial for 5 - 6.5 years

Exclusion criteria:

  • Presence of one or more of the following confounding or complicating problems:
  • Any other active pulmonary disease
  • Any chronic condition presumed to interfere with the successful completion of the project or confound its interpretation
  • Pulmonary function testing findings suggesting a ventilatory defect other than asthma, or evidence of existing irreversible lung damage
  • Severe chronic sinusitis or nasal polyposis
  • Introduction of or a change in allergen immunotherapy within the past month
  • Use of more than 4 sprays of nasal steroids daily (only beclomethasone allowed)
  • Pregnancy
  • Current use of metoclopramide, ranitidine, or cimetidine
  • Treatment for gastroesophageal reflux
  • Participation in another drug study
  • Evidence of severe asthma as indicated by one or more of the following:
  • Two or more hospitalizations for asthma in the past year
  • Six or more steroid bursts in the past year
  • Demonstrated need for continuous use of glucocorticoids, either oral or inhaled
  • When off inhaled O2-agonist for more than 4 hrs and theophylline for more than 24 hrs, FEV1 less than 65% predicted
  • Intubation for asthma at any time in the past
  • Need for 9 or more puffs/day of albuterol for each of 3 consecutive days (excluding preventive use prior to exercise), or nocturnal asthma awakenings more than 1.5 times per week on average, or average diary card symptom code greater than 2, or requirement for other medications to control asthma, during prn screening period
  • Inability to perform 3 acceptable FVC maneuvers of which at least 2 reproducible FEV1s are within 10% of the largest FEV1
  • Inability to complete the methacholine challenge or methacholine PC20 FEV1 greater than 12.5 mg/ml
  • Evidence that patient or family may be unreliable or non-compliant or may move from the metropolitan area before trial completion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000575

Sponsors and Collaborators
Johns Hopkins Bloomberg School of Public Health
National Heart, Lung, and Blood Institute (NHLBI)
CAMP Steering Committee
Layout table for investigator information
Principal Investigator: N. F. Adkinson, MD Johns Hopkins University
Principal Investigator: Anne Fuhlbrigge, MD, MS Brigham and Women's Hospital
Principal Investigator: H. W. Kelly, PharmD University of New Mexico
Principal Investigator: Padmaja Subbarao, MD, MSc The Hospital for Sick Children
Principal Investigator: Paul Williams, MD Asthma, Inc.
Principal Investigator: Robert Strunk, MD Washington University School of Medicine
Principal Investigator: Stanley Szefler, MD National Jewish Health
Principal Investigator: James Tonascia, PhD Johns Hopkins University
Principal Investigator: Robert Zeiger, MD, PhD University of California, San Diego

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: James Tonascia, Principal Investigator, CAMP Data Coordinating Center, Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier: NCT00000575    
Other Study ID Numbers: 213
5U01HL075417 ( U.S. NIH Grant/Contract )
First Posted: October 28, 1999    Key Record Dates
Results First Posted: April 3, 2014
Last Update Posted: April 3, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Mast Cell Stabilizers
Immunologic Factors
Anti-Allergic Agents